ADEQUACY OF DIAGNOSIS AND TREATMENT OF PHARYNGOTONSILLITIS
5PSQ-136
DISPROPORTIONALITY ANALYSIS OF THE SKIN TOXICITY OF INGENOL MEBUTATE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
5PSQ-135
ADEQUACY OF HYPOLIPEMIANT TREATMENT IN PRIMARY HEALTHCARE
5PSQ-134
ANALYSIS OF FACTORS RELATED TO THE CLINICAL COURSE OF COVID-19 INFECTION IN PATIENTS WITH HYPERTENSION
5PSQ-133
EVALUATION OF A QUALITY MONITORING PROGRAMME FOR INTRAVENOUS FLUID MANAGEMENT
5PSQ-132
FAILURE MODE AND EFFECT ANALYSIS APPLIED TO THE PARENTERAL NUTRITION PREPARATION PROCESS IN A MATERNITY AND NEONATAL HOSPITAL
5PSQ-131
ADHERENCE OF THE HOSPITAL CLINICAL MANAGEMENT UNITS TO THE CENTRE'S PROTOCOL FOR THE SAFE USE OF INTRAVENOUS POTASSIUM
5PSQ-130
INTRAVENOUS POTASSIUM CHLORIDE: IS THE MEDICATION USE PROCESS SECURE?
5PSQ-129
MANAGEMENT OF MULTIFACTORIAL ANAEMIA WITH SUBCUTANEOUS DARBEPOETIN WITH INITIAL MONTHLY DOSAGE, OMITTING INDUCTION ACCORDING TO THE TECHNICAL DATA SHEET, IN ELDERLY PATIENTS
5PSQ-128
WHICH ENOXAPARIN PREVENTIVE DOSAGE TO CHOOSE FOR OBESE PATIENTS IN ORTHOPAEDIC SURGERY ?
5PSQ-127
ASSESSING APPROPRIATE DOSING OF NEW ORAL ANTICOAGULANTS: APIXABAN, DABIGATRAN AND RIVAROXABAN IN A TERTIARY HOSPITAL
5PSQ-126
AVICENNE AS A CLINICAL DECISION SUPPORT IN THROMBOPROPHYLAXIS: JUST BECAUSE THE PATIENT’S SITUATION IS IMPROVING DOESN'T MEAN THERE'S NO DRUG RELATED PROBLEM!
5PSQ-125
EFFECT OF A MULTIFACETED CLINICAL DECISION SUPPORT INTERVENTION ON ADHERENCE TO THROMBOPROPHYLAXIS GUIDELINES IN NON-SURGICAL PATIENTS
5PSQ-124
ANTICOAGULATION MANAGEMENT WITHIN A HOSPITAL SETTING: IDENTIFYING RISK FACTORS AFFECTING PATIENT SAFETY
5PSQ-123
SGLT2 INHIBITORS IN TYPE 2 DIABETES PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASES: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS
